Advancing Oncology Treatments
At Corbus, we are dedicated to developing treatments that aim to significantly improve patient outcomes in cancer care. Our approach combines cutting-edge research with compassionate patient care, striving to transform the prognosis for individuals battling cancer.
Redefining Obesity Treatment
We approach obesity treatment with rigorous medical research, developing targeted therapies designed to make lasting health improvements achievable. Our mission is clear: to deliver solutions that enhance quality of life and provide meaningful, sustainable health benefits for patients.
Science Driven by Purpose
At Corbus, we pursue medical advancements grounded in integrity, expertise, and a genuine commitment to improving patient outcomes. Our purposeful research is not just about developing drugs- it is about making a real difference in people's lives while earning the trust of patients, healthcare professionals, and investors alike.
CRB-913 Obesity Treatment Update
Corbus Pharmaceuticals reports results from phase 1a study of oral CB1 inverse agonist CRB-913 for the treatment for obesity demonstrating favorable safety profile and emerging evidence of weight loss.
CRB-913 Advances Through Phase 1a Safety Study